Door Pharmaceuticals, a company founded by MCB faculty member Adam Zlotnick, presented a paper at the International HBV Meeting (September 21, 2021). Members of the Door team showed that a small molecule that binds the HBV core protein could suppress HBV production. The Door team speculates that the molecule acts by inhibiting transcription of viral RNA.
The College of Arts